Oxitropium bromide

In today's world, Oxitropium bromide is a topic that has gained great relevance in different areas. Whether in politics, science, technology or culture, Oxitropium bromide has captured the attention of millions of people around the world. Its impact has been so significant that it has generated debates and reflections in contemporary society. In this article, we will explore the phenomenon of Oxitropium bromide in depth, analyzing its many facets and its influence on everyday life. From its origins to its present, we will take a tour of Oxitropium bromide to understand its importance today and its projection in the future.

Oxitropium bromide
Clinical data
Trade namesOxivent, Tersigan, Tersigat, Ventilat
Other namesN-Ethylscopolammonium bromide; Ba 253; Ba 253BR-L; Ba 253Br; Hyoscine ethobromide; N-Ethylnorscopolamine methyl bromide; Scopolamine ethobromide
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • (8r)-6β,7β-Epoxy-8-ethyl-3α-hydroxy-1αH,5αH-tropanium bromide (−)-tropate
CAS Number
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.045.543 Edit this at Wikidata
Chemical and physical data
FormulaC19H26BrNO4
Molar mass412.324 g·mol−1
3D model (JSmol)
  • .OC(c1ccccc1)C(=O)O2C34O4(C2)3(C)CC
  • InChI=1S/C19H26NO4.BrH/c1-3-20(2)15-9-13(10-16(20)18-17(15)24-18)23-19(22)14(11-21)12-7-5-4-6-8-12;/h4-8,13-18,21H,3,9-11H2,1-2H3;1H/q+1;/p-1/t13-,14-,15-,16+,17-,18+,20?;/m1./s1
  • Key:LCELQERNWLBPSY-KHSTUMNDSA-M

Oxitropium bromide (trade names Oxivent, Tersigan) is an anticholinergic used as a bronchodilator for the treatment of asthma and chronic obstructive pulmonary disease.

It was patented in 1966 and approved for medical use in 1983.

References

  1. ^ Restrepo RD (July 2007). "Use of inhaled anticholinergic agents in obstructive airway disease". Respiratory Care. 52 (7): 833–51. PMID 17594728.
  2. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 447. ISBN 9783527607495.